Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Stifel Nicolaus Adjusts Price Target for Johnson & Johnson to $180 From $155, Maintains Hold Rating

01/27/2021 | 09:23am EDT


ę MT Newswires 2021
All news about JOHNSON & JOHNSON
02:50pJOHNSON & JOHNSON : to Participate in the Virtual Wells Fargo Healthcare Confere..
PU
11:26aJOHNSON & JOHNSON : Single-Shot COVID-19 Vaccinations to Resume in the U.S. for ..
AQ
06:06aJOHNSON & JOHNSON : Mozambique to Vaccinate 20 Per Cent of Its Target By Septemb..
AQ
07/26ASPEN PHARMACARE : To Send First Batch Of Johnson & Johnson Jab To South Africa ..
MT
07/23Relaxed Border Restrictions For U.S. Travelers Coming August 9, 2021
AQ
07/23GLOBAL MARKETS LIVE : Intel, HoneyWell, American Express, Visa, Twitter...
07/23JOHNSON & JOHNSON : UBS Adjusts Johnson & Johnson's Price Target to $183 From $1..
MT
07/23ASTRAZENECA : EU On Track To Donate 200 Million COVID-19 Vaccine Doses In 2021
MT
07/22JOHNSON & JOHNSON : Opioid-ravaged West Virginia looks to $26B deal for help
AQ
07/22JOHNSON & JOHNSON : In opioid-ravaged WVa, potential deal raises hopes for help
AQ
More news
Financials (USD)
Sales 2021 94 447 M - -
Net income 2021 22 808 M - -
Net Debt 2021 871 M - -
P/E ratio 2021 20,2x
Yield 2021 2,40%
Capitalization 455 B 455 B -
EV / Sales 2021 4,82x
EV / Sales 2022 4,61x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 171,87 $
Average target price 184,35 $
Spread / Average Target 7,26%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
NOVARTIS AG-0.17%221 954
ELI LILLY AND COMPANY44.05%221 084
ABBVIE INC.9.93%208 043